VTAK Research | Milton Maxwell

VTAK

Catheter Precision, Inc.

2.1900

-0.0450-2.01%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap

3.65M

P/E (TTM)

0.06

Basic EPS (TTM)

36.33

Dividend Yield

Recent Filings

8-K

11/21/25Nov 21, 2025

10-Q

11/13/25Nov 13, 2025

8-K

Stockholders approve share increase

10/15/25Oct 15, 2025

Catheter Precision stockholders approved an amendment on October 10, 2025, boosting authorized common shares from 60 million to 500 million, with 497,162 votes for and 133,882 against at the special meeting. They also ratified WithumSmith+Brown, PC as auditors for fiscal 2026, garnering 610,134 yes votes. This share increase equips the company for potential equity raises. Yet opposition signals investor caution.

8-K

UK Approval for LockeT

8/18/25Aug 18, 2025

Catheter Precision secured approval for its LockeT suture retention device in the United Kingdom on August 18, 2025, following CE Mark clearance in May 2025. The company partnered with distributor HC21 to drive commercialization, aiming to boost patient comfort, speed recovery, and enable earlier discharges after cardiac procedures. This supports NHS efforts to cut waiting lists. Yet competition looms large.

8-K

1-for-19 reverse split executed

8/15/25Aug 15, 2025

Catheter Precision executed a 1-for-19 reverse stock split, effective August 15, 2025, slashing outstanding shares from 23,327,516 to 1,227,764 while preserving ownership percentages. No fractional shares issued; holders get pro rata cash from sales instead. Adjustments hit options, warrants, and registration statements proportionally. This sharp cut aims to meet NYSE American standards, yet risks diluting liquidity further.

About

Catheter Precision, Inc. designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also offers LockeT, a suture retention device that temporarily secure sutures and aid clinicians in locating and removing sutures. The company is based in Fort Mill, South Carolina.

CEO

Mr. David A. Jenkins

IPO

9/27/2018

Website

https://www.catheterprecision.com

Employees

Sector

Healthcare

Industry

Medical Devices